A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 13, 2013

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions
Castration Resistant Prostate Cancer
Interventions
DRUG

Abiraterone Acetate

"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"

DRUG

Prednisone

5 mg, twice daily, oral administration

Trial Locations (2)

79239

Oregon Health and Science University, Portland

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Biotech, Inc.

INDUSTRY

lead

Terence Friedlander, MD

OTHER

NCT01637402 - A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter